Human peptide trials have involved small sample sizes and, sometimes, loose protocols with no blinding or placebo controls
Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M, Tsuchida S
Nitric oxide (NO) accumulation mediated by glutamate receptors (GLRs) is a hallmark of neuronal dysfunction and has been linked to the pathogenesis of several neurodegenerative diseases
One study used 300 milligrams a day for four months with good tolerance
Jetlag Recovery : Travel fatigue is real: it weakens the immune system & dehydrates tissue
It is estimated that CagriSema could hit the market by late 2025 or early 2026, pending the outcome of Novo Nordisk s phase 3 trials, expected later this year and in early 2025